CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma

The is a prospective, open-label, dose-climbing clinical study assessing the efficacy and safety of CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 15 subjects with r/r CD30+ lymphoma。

Trial Details

NCT ID
NCT06850285
Phase
NA
Sponsor
Shanxi Bethune Hospital
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • chimeric antigen receptor gene modified T cells
Locations (sample)
  • Taiyuan, Shangxi, China|37.86944,112.56028

Key Eligibility Criteria

  • Age≥15 years and ≤80years,female and male;
  • CD30+ lymphocyte malignancies;
  • CD30 expression \>10% by immunohistochemistry;
  • At least 1 measurable lesion can be measured according to theLugano 2014 evaluation criteria;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →